Commercial/Healthcare Exchange PA Criteria

Effective: April 27, 2020

Prior Authorization: Xuriden

Products Affected: Xuriden (Uridine triacetate)

Medication Description:
Hereditary orotic aciduria is an extremely rare (less than 20 cases identified worldwide) autosomal recessive disorder attributed to an inborn error of pyrimidine metabolism that is recessively inherited. This disorder is characterized by an onset in early infancy, growth failure, developmental delay, hypochromic anemia, and excessive urinary excretion of orotic acid, an intermediary of uridine synthesis. Orotic aciduria causes a characteristic form of anemia and may be associated with mental and physical retardation. Orotic acid is an intermediate product in pyrimidine synthesis pathway, a subsequent product of which plays a role in conversion between dihydrofolate and tetrahydrofolate. Orotic aciduria is associated with megaloblastic anemia due to decreased pyrimidine synthesis, which leads to decreased nucleotide-lipid cofactors needed for erythrocyte membrane synthesis in the bone marrow.

Xuriden, a pyrimidine analog, is the first FDA approved treatment for hereditary orotic aciduria. Xuriden was granted orphan drug. There are no contraindications, warnings or serious adverse events reported with uridine triacetate.

Covered Uses:
1. Hereditary orotic aciduria

Exclusion Criteria: None

Required Medical Information:
1. Documentation of diagnosis

Age Restrictions: None

Prescriber Restrictions: None

Coverage Duration: 12 months

Other Criteria: None

References:
1. Xuriden [package insert]. Gaithersburg, MD: Wellstat Therapeutics Corporation; September 2015.
2. Sutton V. Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features. In: UpToDate, Hahn S (Ed), UpToDate, Waltham, MA (accessed December 21, 2015).

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	4/20/2016
2	Policy Update	CCI adoption of EH policy Removal from CCI PA to Indication Policy	Reviewed covered uses and contraindications to FDA label	4/27/2020